Organization Profile

You just read:

Analysis of real-world safety data shows gut-selective ENTYVIO® (vedolizumab) had fewer serious infections and adverse events than those on systemic TNFα-antagonist therapy in ulcerative colitis and Crohn's disease patients

News provided by

Takeda Canada Inc.

Jun 05, 2018, 07:00 ET